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Background: Telomerase is a ribonucleoprotein that adds TTAGGG nucleotide repeats onto the ends of eukaryotic chromosomes to maintain telomere integrity. Somatic cells do not express telomerase and stop dividing when the chromosomal ends are shortened critically after many cell divisions. Immortal cell lines and cancer ceils apparently have telomerase activity that contributes to an unlimited number of cell cycles. The purpose of our study is to investigate whether telomerase activity is expressed in primary malignant tumors of the skeletal system when compared to adjacent normal tissue.
Methods: Fresh tumor and normal tissue was collected from 14 patients (10 males, 4 females; age range, 8 to 76 years) and protein extraction performed. The tumors included seven osteosarcomas (three examined before and after chemotherapy), two chondrosarcomas, two spindle cell tumors, one hemangiopericytoma, one chordoma, and one adamantinoma. Telomerase activity was analyzed by using a highly sensitive polymerase chain reaction (PCR)-based assay (telomere repeat amplification protocol [TRAP] ).
Results: Telomerase activity was found in 8 of 14 sarcoma patients (57%) using the TRAP assay. Compared to HeLa cell extract (positive control), telomerase activity in the tumor specimen ranged from 0 (in osteosarcoma) to 11.7% (in hemangiopericytoma). There was variation in the number of telomeric repeats generated by telomerase. At least five telomeric bands (e.g. 50, 56, 62, 68, 74 bp) in a ladder pattern had to be present before telomerase activity was considered positive in our analysis.
Conclusions: Telomerase activity may be an oncogenic sustaining event helping to maintain the transformed phenotype seen in malignant tumors of the bone. The degree of telomerase activity varies among skeletal malignancies, but was tess than that observed in HeLa cells. The majority of osteosarcomas showed no telomerase activity.
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Primary malignant tumors of the skeletal system are rare. About 2000 new skeletal sarcomas are reported annually in the United States. 10steosarcoma is the most common primary malignancy of bone. Approximately 750 individuals develop conventional osteosarcoma each year in the United States. 2 Advances in medical imaging, chemotherapy, bioengineering, and surgical technique have improved the prognosis and functional outcome in the treatment of skeletal sarcomas. 3'4 Survival results have plateaued, however, as chemoresistant sarcomas predominate, s New antineoplastic drugs and tumoricidal concepts require investigation.
Telomeres are specialized structures at the ends of eukaryotic chromosomes containing unique (TTAGGG)n repeats. The average telomere length in humarls is between 5 and 15 kilobases. These repeats protect chromosome ends against illegitimate recombination and may direct chromosome attachment to the nuclear membrane. Their structure and mode of synthesis allow for replication of the chromosome ends; however, loss of chromosome terminal sequences occurs with each round of replication. Previously, we demonstrated loss of telomere size in leukocytes of healthy individuals of advancing age (average 40 base pairs per year), with the greatest loss occurring in the younger subjects, those less than 20 years of age. 6 Reduction in telomere length has been observed in several malignancies, including colon, glioblastoma, leukemia, Wilms, breast, lung, and giant cell tumor of bone, as well as the in vitro senescence of human fibroblasts. 7<3
Telomeres appear elongated in fetal tissues, and the size is more homogeneous than in older individuals, in whom telomeres are shorter and more heterogeneous in size. 14 Telomere integrity is maintained by a specific telomere transferase (telomerase), a ribonucleoprotein enzyme. Telomerase contains an RNA component that has a template region complementary to the (TTAGGG)n repeats that permit the de novo synthesis of telomeric DNA at the chromosome ends. Telomerase counteracts molecular senescence or telomere loss and is most active in germ cells, which have significantly longer telomeres than do somatic cells, in which telomerase is inactive and telomere shortening occurs naturally. The reactivation of telomerase in malignant cells may allow for stabilization of the telomere and may be important for the attainment of immortality by cancer cells. Telomerase activity has been reported in tumor cells, initially in giant cell tumor of bone is and ovarian cancer. 16 Recently, a highly sensitive polymerase chain reaction (PCR)-based telomerase assay called the telomerase repeat amplification protocoI (TRAP) method has been developed for telomerase detection. I7 Using this method, telomerase activity has been found in a wide variety of tumors, including neuroblastoma, is lung cancer, 19 colorectal cancer, 2° hepatocellular carcinoma, 2t gastric cancer, 22 breast cancer, 23 squamous cell carcinoma, 24 and retinoblastomaY There is a paucity of telomerase data from skeletal sarcomas. In the present study, telomerase activity is assayed in several skeletal sarcomas and compared with their clinical outcome.
PATIENTS AND METHODS

Patients and Tissue Samples
A total of 14 patients (10 male, 4 female) with skeletal sarcomas (10 osteosarcomas--7 patients before chemotherapy [3 of whom were also studied after chemotherapy]; 2 chondrosarcomas, 2 spindle cell tumors, 1 chordoma, 1 adamantinoma and 1 hemangiopericytoma) were included in this study. Seventeen tumor samples measuring 1 cm 3 were obtained intraoperatively from the 14 patients after informed consent. The average age of the patients was 42.8 years (range, 8 to 76 years). Clinical characteristics and descriptions of the patients are shown in Table 1 . The tumor specimens used in our analysis were carefully selected from biop- * High grade = poorly differentiated tumor, high mitotic rate, likely to metastasize; low grade = well differentiated minor, low mitotic rate, likely to recur locally.
? Telomerase activity was present when at least five telomere repeat bands (e.g., 50, 56, 62, 68, 74 bp) were detected by the Phoshoimager (Molecular Dynamics, Sunnyvale, CA). sies or surgical resections. Only tumor from the core or middle of the tumor specimen was analyzed, to increase the likelihood that the tumor specimen contained neoplastic cells. Pathological documentation of all tumors was performed. Non-tumor tissue specimens (I cm3), usually muscle, also were collected from surrounding sites for telomerase analysis as a negative control. Immediately after collection the specimen was placed on wet ice, frozen in liquid nitrogen, and stored at -80°C. The time from collection of the tissue specimen to storage did not exceed 30 minutes. HeLa cells were used as telomerase-positive control cells and were obtained commercially (National Institute of General Medical Sciences, Human Genetic Mutant Cell Repository, Camden, N J).
Telomerase Assay
The tissue specimens were partially thawed, weighed, and 100 mg used for protein extraction. The tissue specimen was thoroughly washed with PBS buffer, then transferred to homogenizer tubes containing 200 txl cold (4°C) CHAPS lysis buffer (10 mM tris-HC1 (pH 7.5), 1 mM MgC12, 1 mM EGTA, 0.1 mM Benzamidine, 5 mM beta-mercaptoethanol, and 0.5% CHAPS, 10% glycerol) and dispersed by a motorized homogenizer (Kontes, Vineland, NJ) following the manufacturer's instructions. Disposable pestles were used for each specimen. The homogenized samples were incubated at 4°C for 10 minutes, after which the cell lysate was spun at 14,000 rpm at 4°C for 30 minutes. Protein concentration was determined by the Bradford Assay (BioRad Laboratories, Richmond, CA). The supernatants were then aliquoted and stored at -80°C.
Telomerase assay was undertaken using the Trap-eze Telomere Kit from Oncor, Inc. (Gaithersburg, MD) and following the manufacturer's protocols. Radioactive isotope (32P) was used for the PCR method. The telomerase products were amplified for 30 minutes at 30°C, then for 27 cycles at 94°C for 30 seconds and at 60°C for 30 seconds. 1.5 p~L of PCR products were loaded onto an 18-cm electrophoresis apparatus using 12% polyacrylamide gel and were run for 2 hours and 30 minutes at 500 volts. The dried gel was exposed to a Phosphoimager Screen (Molecular Dynamics, Sunnyvale, CA) and analyzed by the use of the Phosphoimager of the radioactive telomeric fragments generated by the TRAP telomerase assay, following the manufacturer's protocol. Telomerase products were also heat inactivated at 95°C for 10 minutes and treated with 1 IxL of RNase (10 mg/mL) for 30 minutes. Heat and RNase individually destroyed telomerase activity in the samples studied. Negative telomerase activity was recorded after 7 days of exposure to the Phosphoimager Screen. Positive activity was recorded after detection of 5 telomefic bands in a 6-bp repeat ladder pattern (e.g., 50, 56, 62, 68, 74 bp) identified by the Phosphoimager and the presence of the positive internal control 36-bp band. Telomerase activity was quantified by detecting radioactivity from the telomeric band formation in a ladder fashion and compared relatively to a HeLa ceil extract treated similarly for telomerase activity with a protein concentration of 0.0006 Ixg. Higher protein concentrations showed inhibitions of telomerase activity, whereas lower concentrations showed lower activity, which agrees with other investigators. The optimal protein concentration for HeLa cells was 0.0006 txg, which was used for comparison with protein extracts from tumor cells. Tumor protein concentrations of 0.3 tzg, 0.03 tzg, and 0.003 p~g were chosen for comparison with the HeLa cell extracts. The level 0.03 txg was considered the optimal concentration for all tumors studied. On all occasions the protein samples were restudied, and the telomerase results were similar on the repeated measures. Therefore, the telomerase findings were reproducible with this methodology.
Histopathology
To determine if the number and percentage of tumor cells and nonneoplastic cells, mitotic activity, presence of necrosis, and amount and type of extracellutar material influenced telomerase activity, histopathology of each specimen was recorded. An independent pathologic review was undertaken from representative hematoxylin and eosin-stained microscope slides, which reconfirmed the diagnosis. Histopathology was recorded from five representative microscopic high-power fields (40x; 1690 txm 2 surface area/each). The average and standard deviation of cells seen per high-power field and the percentage of neoplastic cells were calculated along with additional histopathology data ( Table 2) .
RESULTS
Seventeen tumor samples were obtained from 14 patients. The clinical data are displayed in Table 1 , and the telomerase data from the skeletal sarcoma patients are shown in Table 3 .
Three patients (9, 10, 11) had tumor specimens collected before and after chemotherapy. It is uncertain how neoplastic cells and telomerase respond to cytotoxic therapy. Telomerase activity was observed in patient 10 with osteosarcoma (after chemotherapy only) and patient 11 with osteosarcoma (before chemotherapy only). Specimens from patient 14 (spindle cell tumor) and pa- Eight of the 14 patients (57%) studied showed telomerase activity. Three of the i0 osteosarcoma specimens from seven patients showed low telomerase activity (0.2%, 0.4%, and 0.5%) compared to the HeLa cell extract used as a positive telomerase control. Both spindle cell tumors, which are undifferentiated tumors compared to osteosarcomas, also had detectable but low (0.3%) telomerase activity compared with HeLa. Adamantinoma, chondrosarcoma, and hemangiopericytoma specimens showed telomerase activity of 3.1%, 3.9%, and 11.2%, respectively, compared with HeLa (Fig. 1) . In five of the eight tumor cases, telomerase activity was also found in a 10-fold dilution (0.003-txg protein concentration) compared to a 0.03-1xg concentration, but in decreased levels. In the tumor specimens with the 0.03-btg protein concentration, the telomerase activity ranged from 0.3% to 11.2% of activity seen in HeLa at a concentration of 0,0006 ~g. In two telomerase-positive samples, activity was observed only in the 0.03-btg tumor protein concentration. In most telomerase-positive rumor specimens, weak to moderate telomeric band signals were detected by the Phosphoimager, and 9 to 11 * Optimal tumor protein concentration for detection of telomerase activity was 0.03 ixg; higher concentrations inhibited telomerase activity in most tumor specimens. *, Telomerase activity was considered negative after 7 days exposure to the Phosphoimager (Molecular Dynmnics, Sunnyvale, CA).
bands were observed. Several tumors, such as adamantinoma and hemangiopericytoma, showed an intense 6-bp repeat telomeric band ladder pattern in the first six telomere bands (50, 56, 62, 68, 74, 80 bp).
Other tumors, e.g., osteosarcomas and chondrosarcomas, had 9 to 11 telomeric bands detected by the Phosphoimager but showed, on average, weaker band signals. In all subjects, normal tissue (e.g., muscle) was collected at the time of tumor removal and telomerase activity examined. No telomerase activity was seen in the normal tissue.
Cell density varied among the skeletal sarcomas studied as well as within the tumor subgroups. For example, patient 8 (osteosarcoma) showed 555 tumor cells per high-power field, and patient 10a (osteosarcoma) showed 109 tumor cells. Both were studied before chemotherapy. The highest telomerase activity was seen in patient 4 (hemangiopericytoma), with the largest number of tumor cells observed per microscope high-power field. However, the second, third, and fourth largest number of tumor cells observed per high-power field were in osteosarcoma patients with no detectable telomerase activity. In addition, the lowest number of tumor cells was found in patient 1 lb (osteosarcoma), who had been treated with chemotherapy.
There appeared to be no correlation with mitotic activity, grade, metastasis, presence of necrosis or extracellular material, and telomerase activity. For example, two of the three osteosarcoma patients with marked osteoid material (patients 10b and 1 la) showed telomerase activity. Two of the three tumors with muttinucleated cells (patients 1 and 14) seen per high-power field showed telomerase activity. Fourteen of the 17 tumors were classified as high grade, including all osteosarco- There appeared to be no correlation between age and telomerase activity. Telomerase activity was seen in patients ranging from 17 to 61 years of age. The percentage of tumor cells seen per high-power field ranged from 41% in patient 1 lb (osteosarcoma after chemotherapy) to 98% in patient 4 (hemangiopericytoma). No telomerase activity was observed in patients with under 69% tumor cells in our study. The average percentage of tumor cells in those patients exhibiting telomerase activity was 87%.
To investigate for inhibition of the TRAP assay we examined different tumor protein concentrations (0.3 Ixg, 0.03 b~g, and 0.003 Ixg). In most cases, inhibition was observed at 0.3-txg concentration, with a decreased intensity and number of telomeric bands recognized. An additional band located between the 36-bp internal control band and the 50-bp band was found in those specimens showing inhibition, For the telomerase activity to be considered positive, at least five telomeric bands (50, 56, 62, 68, 74 bp) were present. Therefore, we chose the tumor protein concentration of 0.03 pog to be optimal for all tumor specimen assays to compare with the tetomerase positive controls (e.g., HeLa). A similar procedure for determining telomerase inhibition of the HeLa cell extract was also undertaken. The optimal protein concentration for HeLa cell extract was determined to be 0.0006 txg (Fig. 2) .
DISCUSSION
Telomerase activity was present in most of the skeletal sarcomas, either before or after chemotherapy. We compared the tumor TRAP assay signal densitometrically with a HeLa cell extract of known protein concentration and expressed the telomerase activity in percentage compared with HeLa. The range of telomerase activity was studied in different tumor concentrations to determine whether telomerase was inhibited at higher than optimal concentrations. The tumor and HeLa extracts were treated separately with heat and RNase to further confirm the presence of telomerase activity, which is inactivated by either treatment. The number of Phosphoimagerdetected telomeric repeat bands also was recorded and telomerase activity compared with the clinical characteristics of each patient.
The data suggest that skeletal sarcomas have a much lower telomerase activity using the TRAP protocol than do HeLa cells, which represent a highly malignant tumor cell line commercially available and used as a telomerase positive control in our study. Gupta et al. 25 reported no detectable telomerase activity from an osteosarcoma cell line. We found no detectable telomerase activity in the original or the repeated assays in five of the seven freshly harvested osteosarcoma specimens examined before chemotherapy. We also :found no telomerase activity (data not shown) in a benign chondroblastoma from the left humerus of a 15-year-old female. Bryan et al.26 also reported no telomerase activity in immortal cells derived from fibroblasts and suggested that in some tumor cells telomere maintenance may be related to non-telomerase factors. Our observation of low levels of telomerase activity in skeletal sarcoma specimens compared with HeLa supports our earlier reports of low levels of telomerase activity in chordomas 27 and in giant cell tumor of bone 15 using the S-100 cell extraction protocols reported by Counter et al. 28 and Morin 29 and not based on the TRAP assay. The similar reported telomerase activity levels using different assays are evidence confirming that each assay is correct.
Histopathologic review revealed no correlation between mitosis, grade, necrosis, or extracellular material found in comparison with the telomerase activity recorded. Although our sample size is relatively small, the number of tumor cells seen may influence the TRAP protocol results. Sarcomas with the highest tumor cell density (i.e., hemangiopericytoma) showed the highest telomerase activity. This phenomenon of increased number of tumor cells and increased telomerase activity has been observed previously in in vitro experiments. 17
Chemotherapy also may influence telomerase activity. For example, no telomerase activity was found in a recurrent osteosarcoma following chemotherapy (patient 1 lb). Those sarcomas with a high number of tumor cells (e.g., osteosarcoma patients 8, 9a, 9b) but with no telomerase activity may reflect genetic abnormalities. These genetic derangements could affect telomerase gene expression or its translation and not allow telomerase production. Telomerase activation may be passively coselected as tumors develop or following the administration of neoadjuvant chemotherapy.
In our study we used a highly sensitive PCR-based telomeric repeat amplification protocol (TRAP) following the manufacturer's guidelines, which allow for telomerase detection in cell extracts (Oncor Inc., Gaithersburg, MD). Several potential problems that may influence the qualitative and quantitative results of telomerase detection have been described. 3°'31 For instance, in some tissues, Taq polymerase inhibitors may be present, giving false-negative results. In addition, the assays used in the past were non-linear, which made the relative telomerase expression difficult to interpret in some tumors. With modification of the TRAP protocol and recognition of factors influencing telomerase activity (e.g., inhibition), the telomeric repeat amplification protocol has been much improved, 32 with more reproducible results, and successfully applied in our study.
We conclude that eight of the 17 skeletal sarcoma samples demonstrated telomerase activity. Because telomerase activity was :found in 57% of our patients, levels of activity may reflect the different cell populations rather than the overall number of telomerase positive cells. 19 Identifying telomerase activity in skeletal sarcomas is of interest, because efforts currently are underway to develop telomerase inhibitors to serve in multi-agent chemotherapy protocols, 33 and potentially to augment the treatment strategy for sarcomas. It appears that skeletal sarcoma cells have other ways of maintaining stability at the ends of their chromosomes. Telomerase may be helpful, but is not essential, for skeletal sarcoma oncogenesis.
